The pill formulation of zanubrutinib (Brukinsa; BeOne) is currently approved for all five indications across various hematological cancers.Just one explanation why the price tag is so higher is always to deal with The prices of acquiring and making the drug. The value paid from the NHS for this just one-off therapy must be set in opposition to the